 Magenta Therapeutics NASDAQ: MGTA, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported the presentation of preclinical data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. Magenta also highlighted data from its Phase 1 study of first-line stem cell mobilization therapy MGTA-145. These results were presented this week at the European League Against Rheumatism EULAR annual meeting. 